Citations

Clear

634 citation(s) found for "Hall, A".

Working Toward Consensus on Sporadic Vestibular Schwannoma Care: A Modified Delphi Study
Carlson, Matthew L. , Link, Michael J., Driscoll, Colin L. W., Haynes, David S. , Billings, Heather , Lohse, Christine M. , Hall, Elissa R., Barker, Frederick G., Brackmann, Derald E., Cueva, Roberto A., Golfinos, John G. , Gurgel, Richard K. , Kondziolka, Douglas , Kutz, Joe Walter , Neff, Brian A., Sheehan, Jason P. , Yu, Chung Ping, Gurgel, Richard Klaus , Billings, Heather , Kondziolka, Douglas , Link, Michael J. , Agazzi, Siviero , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | November 9, 2020 | Volume: 41 | Issue: 10 | Pages: e1360-e1371

10.1097/mao.0000000000002917 | PMID 33492814 Get It

Objective:To address variance in clinical care surrounding sporadic vestibular schwannoma, a modified Delphi study was performed to establish a general framework to approach vestibular schwannoma care. A multidisciplinary panel of experts was established with deliberate representation from key stakeholder societies. External validity of the final statements was assessed through an online survey of registered attendees of the 8th Quadrennial International Conference on Vestibular Schwannoma.Study Design:Modified Delphi method.Methods:The panel consisted of 16 vestibular schwannoma experts (8 neurotology and 8 neurosurgery) and included delegates representing the AAOHNSF, AANS/CNS tumor section, ISRS, and NASBS. The modified Delphi method encompassed a four-step process, comprised of one prevoting round to establish a list of focus areas and three subsequent voting rounds to successively refine individual statements and establish levels of consensus. Thresholds for achieving moderate consensus, at ≥67% agreement, and strong consensus, at ≥80% agreement, were determined a priori. All voting was performed anonymously via the Qualtrics online survey tool and full participation from all panel members was required before procession to the next voting round.Results:Through the Delphi process, 103 items were developed encompassing hearing preservation (N = 49), tumor control and imaging surveillance (N = 20), preferred treatment (N = 24), operative considerations (N = 4), and complications (N = 6). As a result of item refinement, moderate (4%) or strong (96%) consensus was achieved in all 103 final statements. Seventy-nine conference registrants participated in the online survey to assess external validity. Among these survey respondents, moderate (N = 21, 20%) or strong (N = 73, 71%) consensus was achieved in 94 of 103 (91%) statements, and no consensus was reached in 9 (9%). Of the four items with moderate consensus by the expert panel, one had moderate consensus by the conference participants and three had no consensus.Conclusion:This modified Delphi study on sporadic vestibular schwannoma codifies 100% consensus within a multidisciplinary expert panel and is further supported by 91% consensus among an external group of clinicians who regularly provide care for patients with vestibular schwannoma. These final 103 statements address clinically pragmatic items that have direct application to everyday patient care. This document is not intended to define standard of care or drive insurance reimbursement, but rather to provide a general framework to approach vestibular schwannoma care for providers and patients.
Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel
Kunkle, Brian W. , Schmidt, Michael A. , Klein, Hans‐Ulrich , Hamilton‐Nelson, Kara L., Larson, Eric B., Evans, Denis A., Jager, Phil L. De, Crane, Paul K. , Buxbaum, Joseph D. , Ertekin‐Taner, Nilüfer , Barnes, Lisa L. , Fallin, M. Daniele , Go, Rodney C.P., Obisesan, Thomas O. , Bennett, David A. , Hall, Kathleen, Goate, Alison , Foroud, Tatiana M., Martin, Eden R. , Wang, Li‐San , Byrd, Goldie S. , Haines, Jonathan L. , Schellenberg, Gerard D., Mayeux, Richard , Pericak‐Vance, Margaret A. , Reitz, Christiane, Perrie, M. Adams, Roger, L. Albin, Liana, G Apostolova, Steven, Eschrich, Craig, S , Clinton, T. Baldwin, Robert, C. Barber, Barral, Sandra, Thomas, Gunther, James, T., Gary, W. Beecham, Eileen, H. Bigio, Thomas, D., Blacker, Deborah, Bradley, F. Boeve, James, D. Bowen, Boxer, Adam, James, R. Burke, Jeffrey, Morris, Nigel, J Cairns, Cynthia, M. Carlsson, Regina, M. Carney, Minerva, M. Carrasquillo, David, Hugh-Jones, Dick, Malcom, Dickson, Dennis, W., Doody, Rachelle S., Duara, Ranjan , Kelley, M. Faber, Thomas, Jaya , Kenneth, B., David, W. Fardo, Martin, Roger, Matthew, P. Frosch, Douglas, R. Galasko, Gearing, Marla , Daniel, Hervé, Gilbert, John, R., Robert, C. Green, John, Harding, Ronald, L. Hamilton, Hardy, John , Lindy, E. Harrell, Lawrence, Steve, Ryan, Mary, Matthew, J. Huentelman, Christine, M Hulette, Gail, P. Jarvik, Jin, Lee‐Way, Karydas, Anna, Mindy, J. Katz, John, S., Joel, H. Kramer, James, J. Lah, Andrew, Peter, Richard, B., Constantine, G. Lyketsos, Malamon, John , Daniel, Chammiran , Martiniuk, Frank , Masliah, Eliezer , Wayne, C. McCormick, Susan, M, Andrew, Nesbit M, McDonough, Stefan, Ann., Canfield, Mesulam, Marsel, Bruce, L. Miller, Carol, A. Miller, Thomas, J. Montine, Amanda, J. Myers, John, M. Olichney, Joseph, E. Parisi, Peskind, Elaine R. , Pierce, Aimee, Wayne, W. Poon, Joseph, F. Quinn, Raj, Ashok , Raskind, Murray A. , Reisch, Joan, S., John, M. Ringman, Erik, D. Roberson, Howard, J. Rosen, Donald, R. Royall, Mark, A. Sager, Julie, A. Schneider, Lon, Su, William, W. Seeley, Small, Scott A. , Sonnen, Joshua, A., Robert, Aiko, Rudolph, E. Tanzi, Juan, Caballero, Debby, W. Tsuang, Vivianna, M. Van Deerlin, Badri, Nabeel, Harry, Vanessa, Vonsattel, Jean Paul, Weıntraub, Sandra , Kathleen, A Welsh-Bohmer, Kirk, C W, Thomas, SubinVarghese, Randall, Linnell B., Wu, Chuang‐Kuo, Steven, G. Younkin, Yu, Lei , Yu, Chang‐En , Graff‐Radford, Neill R. , Martinez, Izri, Ayodele, Temitope , Cantwell, Laura B., Jean‐Francois, Melissa, Kuzma, Amanda , Adams, Lonnie D., Chung, Jaeyoon , Jun, Gyungah , Hendrie, Hugh C. , Reiman, Eric M. , Kowall, Neil W. , Golde, Todd E. , Saykin, Andrew J. , Starks, Takiyah D. , Albert, Marilyn S. , Petersen, Ronald , Sano, Mary , Wısnıewskı, Thomas , Vassar, Robert , Kaye, Jeffrey A., Henderson, Victor W. , DeCarli, Charles , LaFerla, Frank M. , Brewer, James B., Miller, Bruce L. , Swerdlow, Russell H. , Paulson, Henry L. , Trojanowski, John Q. , Chui, Helena C., Rosenberg, Roger N., Craft, Suzanne , Grabowski, Thomas J. , Asthana, Sanjay , Morris, John C. , Strittmatter, Stephen M. , Kukull, Walter A. , Asthana, Sanjay , Jarvik, Gail P. , Cribbs, David H. , Sonnen, Joshua A. , Bennett, David A. , Saykin, Andrew J , Miller, Bruce L , Jarvik, Gail P , Paulson, Henry L , Hardy, John , Morris, John C , Goate, Alison M , Sonnen, Joshua , Barnes, Lisa L , Naj, Adam Christian , Hamilton‐Nelson, Kara L. , Manly, Jennifer J. , Kamboh, M. Ilyas , Farrer, Lindsay A. , Abner, Erin L. , Atwood, Craig, S., Becker, James, T., Eileen, H Bigio, Blacker, Deborah , Cao, Chuanhai , Cruchaga, Carlos , Dickson, Dennis, W., Duara, Ranjan , David, W. Fardo, Farlow, Martin, R., Ferris, Steven H. , Geschwind, Daniel, H., Ghetti, Bernardino , Gilbert, John, R., Håkonarson, Håkon , Honig, Lawrence, S., Huebinger, Ryan, M., Matthew, J Huentelman, Kauwe, John, S.K., Keene, C. Dirk , Kim, Ronald, Leung, Yuk Yee , Li, Ge , Lipton, Richard, B., Marson, Daniel, C., McDavid, Andrew, N., Mesulam, Marsel M. , Bruce, L Miller, Mukherjee, Shubhabrata , O’Bryant, Sid, E., Potter, Huntington , Qu, Liming , Raj, Ashok, Reisberg, ‌Barry , Reisch, Joan, S., Rogaeva, Ekaterina A. , Julie, A Schneider, Schneider, Lon, S., William, W Seeley, Spina, Salvatore , George‐Hyslop, Peter St , Valladares, Otto , Vardarajan, Badri, N., Wilhelmsen, Kirk, C., Williamson, Jennifer , Wingo, Thomas, S., Woltjer, Randall, L., Steven, G Younkin, Zhao, Yi Chen , Logue, Mark W. , Adams, L.D., Vance, Jeffery M. , Cuccaro, Michael L. , Mez, Jesse , Lunetta, Kathryn L. , López, Oscar L. , Leverenz, James B. , Levey, Allan I. , Hyman, Bradley T. , Kaye, Jeffrey A., Eldik, Linda J. Van , Chui, Helena C.

Mayo Clinic

JAMA Neurology | October 19, 2020 | Volume: 78 | Issue: 1 | Pages: 102

10.1001/jamaneurol.2020.3536 | PMID 33074286 Get It

Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate
Hall, William A. , Fishbane, Nick , Xu, Melody, Davicioni, Elai , Den, Robert B. , Dess, Robert T. , Wong, Anthony , Schaeffer, Edward M. , Karnes, R. Jeffrey , Kim, Hyung L. , Klein, Eric A. , Davis, John W. , Ross, Ashley E. , Tosoian, Jeffrey J. , Mehra, Rohit , Salami, Simpa S. , Nguyen, Paul L. , Lawton, C.A., Spratt, Daniel E. , Feng, Felix Y. , Xu, Melody J , Davicioni, Elai , Den, Robert B , Dess, Robert T , Jackson, William C , Wong, Anthony C , Carroll, Peter R , Bismar, Tarek A , Kim, Hyung L , Klein, Eric A , Tosoian, Jeffrey J , Morgan, Todd M , Salami, Simpa S , Spratt, Daniel E , Liu, Yang , Mahal, Brandon A. , Jackson, Will , Cooperberg, Matthew R , Morgan, Todd M.

Mayo Clinic

JCO Precision Oncology | October 16, 2020 | Volume: No volume available | Issue: 4 | Pages: 1228-1238

10.1200/po.20.00013 | PMID 35050780 Get It

PURPOSE Pretreatment estimates of seminal vesicle invasion (SVI) are challenging and significantly influence the management of prostate cancer. We sought to improve current models to predict SVI through the development of an SVI prediction genomic signature. PATIENTS AND METHODS A total of 15,889 patients who underwent radical prostatectomy (RP) with available baseline clinical, pathology, and transcriptome data were retrieved from the GRID registry (ClinicalTrials.gov identifier: NCT02609269 ) and other retrospective cohorts. These data were divided into a training (n = 6,766), test (n = 3,363), and two validation (n = 5,062 and 698) cohorts. Multivariable logistic regression was performed to assess the predictive effect of the genomic SVI (gSVI) classifier in the presence of established nomograms (Partin Tables and Memorial Sloan Kettering Cancer Center [MSKCC]). RESULTS In the training cohort, univariable filtering identified 2,132 genes that were differentially expressed between RP tumors with and without SVI. Model parameters were tuned to maximize the area under the curve (AUC) in the testing cohort, resulting in a logistic generalized linear model with 581 genes. The gSVI model scores range from 0 to 1. In the first validation set, gSVI showed superior discrimination of patients with and without SVI at RP compared with other prognostic signatures trained to predict distant metastasis or clinical recurrence. Of the 698 patients in the second validation set, gSVI combined with the MSKCC nomogram had a superior AUC (0.86) compared with either nomogram individually (0.81). CONCLUSION The gSVI represents a novel and validated expression signature to predict the presence of SVI before treatment with surgery. This genomic tool adds discriminatory power to existing clinical predictive nomograms and may help with pretreatment counseling and decision making.
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial
Voso, Maria Teresa , Larson, Richard A. , Marcucci, Guido , Prior, Thomas W., Krauter, Jürgen, Heuser, Michael , Nomdedéu, Josep , Geyer, Susan M. , Wei, Andrew H. , Sierra, Jorge , Sanz, Miguel Á. , Brandwein, Joseph , Witte, Theo M. de, Niederwieser, Dietger , Appelbaum, Frederick R. , Medeiros, Bruno C. , Tallman, Martin S. , Schlenk, Richard F. , Ganser, Arnold , Cheng, Yuan, Chen, Yin-Miao, Pallaud, Céline , Du, Ling, Piciocchi, Alfonso , Ehninger, Gerhard , Byrd, John C. , Thiede, Christian , Döhner, Konstanze , Stone, Richard M. , Bloomfield, Clara D. , Byrd, John C. , Larson, Richard A , Wei, Andrew H , Jones, Dan M. , Lavorgna, Serena , Walker, Alison , Jansen, Joop H. , Amadori, Sergio , Cheng, Yuan, Döhner, Hartmut , Lo‐Coco, Francesco , Voso, Maria Teresa , Byrd, John C

Mayo Clinic

Blood Advances | October 13, 2020 | Volume: 4 | Issue: 19 | Pages: 4945-4954

10.1182/bloodadvances.2020002904 | PMID 33049054 Get It

Abstract The results from the RATIFY trial (ClinicalTrials.gov: NCT00651261; CALGB 10603) showed that midostaurin combined with standard chemotherapy significantly improved outcomes in patients with FMS-like tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML), compared with placebo. In this post hoc subgroup analysis from the trial, we evaluated the impact of midostaurin in 163 patients with FLT3-tyrosine kinase domain (TKD) mutations. At a median follow-up of 60.7 months (95% CI, 55.0-70.8), the 5-year event-free survival (EFS) rate was significantly higher in patients treated with midostaurin than in those treated with placebo (45.2% vs 30.1%; P = .044). A trend toward improved disease-free survival was also observed with midostaurin (67.3% vs 53.4%; P = .089), whereas overall survival (OS) was similar in the 2 groups. Patients with AML and NPM1mut/FLT3-TKDmut or core binding factor (CBF)–rearranged/FLT3-TKDmut genotypes had significantly prolonged OS with or without censoring at hematopoietic cell transplantation (HCT), compared with NPM1WT/CBF-negative AMLs. The multivariable model for OS and EFS adjusted for allogeneic HCT in first complete remission as a time-dependent covariable, revealed NPM1 mutations and CBF rearrangements as significant favorable factors. These data show that NPM1 mutations or CBF rearrangements identify favorable prognostic groups in patients with FLT3-TKD AMLs, independent of other factors, also in the context of midostaurin treatment.
Diced Cartilage in Fibrin Glue for Dorsal Reconstruction as Part of Staged Paramedian Forehead Flap Reconstruction
Abdel‐Aty, Yassmeen , Prasad, Navin , Hall, S. , Howard, Brittany E. , Hall, Scott R

Mayo Clinic

Journal of Craniofacial Surgery | September 30, 2020 | Volume: 32 | Issue: 3 | Pages: 1140-1142

10.1097/scs.0000000000007161 | PMID 33003154 Get It

Abstract The use of diced cartilage grafting is a powerful tool during rhinoplasty for dorsal augmentation; however, its application to nasal structural reconstruction has rarely been reported. Here we present a unique technique for Mohs defect reconstruction combining diced cartilage graft for dorsal augmentation and a folded paramedian forehead flap for soft tissue. A 54-year-old female presented with recurrent basal cell carcinoma of the nose that had been previously resected 3 times in the past. This was treated with Mohs surgery resulting in a through and through nasal defect. This was reconstructed with a staged folded paramedian forehead flap with staged. Due to a loss of dorsal volume and definition creating an excess supratip break, a diced cartilage graft with fibrin glue and temporalis fascia was used for dorsal augmentation. The use of diced cartilage has regained popularity over the last 2 decades with multiple techniques utilizing diced cartilage alone, wrapped in fascia, covered in fascia, wrapped in oxidized methylcellulose, or solidified with fibrin glue. Literature describing the use of fibrin glue suggests that it improves wound healing by promoting cartilage growth, stabilization, and diffusion of nutrients to the graft. Its malleable nature allows for adjustments after the initial placement. This report demonstrates the viability of diced cartilage graft for dorsal augmentation with a paramedian forehead flap for nasal reconstruction. This technique can serve as a powerful tool for the nasal reconstructive surgeon needing scaffolding to rebuild and define the nasal dorsum.
Pediatric Mandibular Central Giant Cell Granuloma: Neoadjuvant Immunotherapy to Minimize Surgical Resection
Lin, Jason , Mecham, Jeffrey C. , Hall, Stuart R., Oh, Christine , Lettieri, Salvatore C. , Hall, S Ryan, Lettieri, Salvatore, Hall, S. Ryan

Mayo Clinic

Journal of Craniofacial Surgery | September 23, 2020 | Volume: 32 | Issue: 3 | Pages: e267-e269

10.1097/scs.0000000000007112 | PMID 32969939 Get It

Abstract Central giant cell granuloma (CGCG) is a relatively uncommon benign bony lesion accounting for approximately 7% of all non-neoplastic lesions of the jaw. The clinical behavior of CGCG can vary from a slow-growing, painless lesion to fast-growing and locally destructive. When such a lesion involves the mandible, this can be quite debilitating for the patient, inhibiting oral intake and requiring an extensive resection and bone graft reconstruction. The authors present a case of effectively decreasing the surgical morbidity associated with a large and rapidly growing CGCG of the mandible in a pediatric patient. Neoadjuvant immunotherapy with denosumab (human monoclonal antibody) facilitated treatment of the tumor without the need for a large resection which would have otherwise necessitated a vascularized bony mandibular reconstruction. Consideration of neoadjuvant medical management of CGCG as the primary treatment is advocated.
ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncolog
Geller, James I. , Pressey, Joseph G. , Smith, Malcolm A. , Kudgus, Rachel A. , Cajaiba, Mariana M. , Barkauskas, Donald A. , Voss, Stephen D., Dome, Jeffrey S. , Fox, Elizabeth , Weigel, Brenda J. , Reid, Joel M. , Smith, Malcolm A , Pressey, Joseph G , Hall, David , Cho, Steve Y. , Berg, Stacey L.

Mayo Clinic

Cancer | September 22, 2020 | Volume: 126 | Issue: 24 | Pages: 5303-5310

10.1002/cncr.33195 | PMID 32914879 Get It

Background Lorvotuzumab mertansine (IMGN901) is an antibody‐drug conjugate linking an antimitotic agent (DM1) to an anti‐CD56 antibody (lorvotuzumab). Preclinical efficacy has been noted in Wilms tumor, rhabdomyosarcoma, and neuroblastoma. Synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), and pleuropulmonary blastoma also express CD56. A phase 2 trial of lorvotuzumab mertansine was conducted to assess its efficacy, recommended phase 2 dose, and toxicities. Methods Eligible patients had relapsed after or progressed on standard therapy for their tumor type. Lorvotuzumab mertansine (110 mg/m 2 per dose) was administered at the adult recommended phase 2 dose intravenously on days 1 and 8 of 21‐day cycles. Dexamethasone premedication was used. Pharmacokinetic samples, peripheral blood CD56‐positive cell counts, and tumor CD56 expression were assessed. Results Sixty‐two patients enrolled. The median age was 14.3 years (range, 2.8‐29.9 years); 35 were male. Diagnoses included Wilms tumor (n = 17), rhabdomyosarcoma (n = 17), neuroblastoma (n = 12), synovial sarcoma (n = 10), MPNST (n = 5), and pleuropulmonary blastoma (n = 1). Five patients experienced 9 dose‐limiting toxicities: hyperglycemia (n = 1), colonic fistula (n = 1) with perforation (n = 1), nausea (n = 1) with vomiting (n = 1), increased alanine aminotransferase in cycle 1 (n = 2), and increased alanine aminotransferase in cycle 2 (n = 1) with increased aspartate aminotransferase (n = 1). Non–dose‐limiting toxicities (grade 3 or higher) attributed to lorvotuzumab mertansine were rare. The median values of the maximum concentration, half‐life, and area under the curve from zero to infinity for DM1 were 0.87 µg/mL, 35 hours, and 27.9 µg/mL h, respectively. Peripheral blood CD56+ leukocytes decreased by 71.9% on day 8. One patient with rhabdomyosarcoma had a partial response, and 1 patient with synovial sarcoma achieved a delayed complete response. Conclusions Lorvotuzumab mertansine (110 mg/m 2 ) is tolerated in children at the adult recommended phase 2 dose; clinical activity is limited.
Abstract IA02: DNA repair gene promoter methylation patterns adapt and influence PARP inhibitor response
Nesic, Kasenija, Hurley, Rachel M. , McGehee, Cordelia D. , Harrell, Maria I., Zapparoli, Giada V., Musafer, Ashan, Wong, Ming E., Weroha, S. John , Hou, Xiaonan , Negron, Vivian , Peterson, Kevin, Schneider, Paula A., Kondrashova, Olga , Li, Hu, Swisher, Elizabeth M. , Southey, Melissa C. , Dobrovic, Alexander , Wakefield, Matthew J. , Kaufmann, Scott H. , Scott, Clare L.

Mayo Clinic

Clinical Cancer Research | September 1, 2020 | Volume: 26 | Issue: 13_Supplement | Pages: IA02-IA02

10.1158/1557-3265.ovca19-ia02 Get It

Abstract PARP inhibitor (PARPi) resistance in high-grade serous ovarian carcinoma (HGSOC) can be acquired as a result of restored homologous recombination (HR) due to secondary or reversion mutations in HR genes, such as BRCA1, BRCA2, and RAD51C, or due to loss of BRCA1 promoter methylation (meBRCA1). We have demonstrated that homozygous meBRCA1 can be lost or reverted to heterozygous methylation following treatment with platinum-based chemotherapy, resulting in HR-competent PARPi-resistant tumors. RAD51C promoter methylation (meRAD51C) is detected in approximately 2% of HGSOC cases and, as with meBRCA1, is associated with gene silencing and HR deficiency. We are exploring PARPi response in meRAD51C preclinical models to determine clinical relevance. Two patient-derived xenograft (PDX) models of HGSOC with RAD51C gene silencing caused by meRAD51C have distinct meRAD51C profiles (measured by methylation-specific high-resolution melt analysis and targeted bisulfite next-generation sequencing), and different responses to PARPi treatment pressure. PDX PH039 loses methylation and regains RAD51C expression after only 2 cycles of PARPi retreatment (niraparib), resulting in PARPi-refractory tumors by cycle 3-4. Illumina EPIC methylation array analysis of PH039 revealed increasing global methylation losses following each round of PARPi treatment. Lack of meRAD51C stability and rapid development of PARPi resistance in PH039 may be due to the high degree of meRAD51C heterogeneity within the tumor favoring selection of pre-existing HR-competent clones under PARPi pressure. In contrast, PDX 183 has a relatively homogeneous and stable meRAD51C profile. We have multiple examples of using unique PDX models to demonstrate various important features of PARPi resistance, including loss of promoter methylation for BRCA1 vs. RAD51C. Thus, meRAD51C confers response to PARPi in HGSOC, but PARPi treatment pressure can cause loss of methylation and drug resistance in some tumors. The contrasting PARPi responses of these PDX provide a platform for the study of meRAD51C stability in vivo and may present therapeutic opportunities to improve meRAD51C durability and PARPi responses in patients. Citation Format: Kasenija Nesic, Rachel M Hurley, Cordelia McGehee, Olga Kondrashova, Maria I. Harrell, Giada V. Zapparoli, Ashan Musafer, Ming E. Wong, John Weroha, Xiaonan Hou, Hu Li, Vivian Negron, Kevin Peterson, Paula Schneider, Elizabeth M. Swisher, Melissa Southey, Alexander Dobrovic, Matthew Wakefield, Scott H. Kaufmann, Clare L. Scott. DNA repair gene promoter methylation patterns adapt and influence PARP inhibitor response [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr IA02.
Immune checkpoint protein VSIG4 as a biomarker of aging in murine adipose tissue
Hall, Brandon M. , Gleiberman, Anatoli S. , Strom, Evguenia , Krasnov, Peter, Frescas, David, Vujcic, Slavoljub, Leontieva, Olga V. , Antoch, Marina P. , Kogan, V. R., Koman, Igor , Zhu, Yi , Kirkland, James L. , Chernova, Olga , Tchkonia, Tamara, Gudkov, Andrei V , Zhu, Yi , Kogan, Valeria, Tchkonia, Tamar

Mayo Clinic

Aging Cell | August 28, 2020 | Volume: 19 | Issue: 10 | Pages: No page available

10.1111/acel.13219 | PMID 32856419 Get It

AbstractAdipose tissue is recognized as a major source of systemic inflammation with age, driving age‐related tissue dysfunction and pathogenesis. Macrophages (Mφ) are central to these changes yet adipose tissue Mφ (ATMs) from aged mice remain poorly characterized. To identify biomarkers underlying changes in aged adipose tissue, we performed an unbiased RNA‐seq analysis of ATMs from young (8‐week‐old) and healthy aged (80‐week‐old) mice. One of the genes identified, V‐set immunoglobulin‐domain‐containing 4 (VSIG4/CRIg), encodes a Mφ‐associated complement receptor and B7 family‐related immune checkpoint protein. Here, we demonstrate that Vsig4 expression is highly upregulated with age in perigonadal white adipose tissue (gWAT) in two mouse strains (inbred C57BL/6J and outbred NIH Swiss) independent of gender. The accumulation of VSIG4 was mainly attributed to a fourfold increase in the proportion of VSIG4+ ATMs (13%–52%). In a longitudinal study, VSIG4 expression in gWAT showed a strong correlation with age within a cohort of male and female mice and correlated strongly with physiological frailty index (PFI, a multi‐parameter assessment of health) in male mice. Our results indicate that VSIG4 is a novel biomarker of aged murine ATMs. VSIG4 expression was also found to be elevated in other aging tissues (e.g., thymus) and was strongly induced in tumor‐adjacent stroma in cases of spontaneous and xenograft lung cancer models. VSIG4 expression was recently associated with cancer and several inflammatory diseases with diagnostic and prognostic potential in both mice and humans. Further investigation is required to determine whether VSIG4‐positive Mφ contribute to immunosenescence and/or systemic age‐related deficits.
Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study
James, Spencer L , Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Sylte, Dillon O , Bertolacci, Gregory J, Cunningham, Matthew , LeGrand, Kate E , Abdelalim, Ahmed , Abdulkader, Rizwan Suliankatchi , Abedi, Aidin , Abegaz, Kedir Hussein , Eshete, Akine , Abushouk, Abdelrahman Ibrahim , Adebayo, Oladimeji , Advani, Shailesh M, Agudelo‐Botero, Marcela , Ahmad, Tauseef , Aichour, Miloud Taki Eddine, Alahdab, Fares , Alanezi, Fahad , Alema, Niguse Meles , Wassihun, Biresaw , Ali, Beriwan Abdulqadir, Alipour, Vahid, Almasri, Nihad A. , Altirkawi, Khalid A , Amer, Yasser Sami , Andrei, Cătălina Liliana , Ansari-Moghaddam, Alireza, Antonio, Carl Abelardo T, Anvari, Davood , Appiah, Seth Christopher Yaw , Arabloo, Jalal , Arefi, Zohreh , Aremu, Olatunde , Ariani, Filippo , Arora, Amit , Quintanilla, Beatriz Paulina Ayala , Ayano, Getinet , Ayanore, Martin Amogre , Azarian, Ghasem , Badawi, Alaa, Badiye, Ashish , Baig, Atif Amin , Bairwa, Mohan , Bakhtiari, Ahad , Banerjee, Srikanta , Banik, Palash Chandra , Banstola, Amrit , Barker‐Collo, Suzanne , Bärnighausen, Till , Barzegar, Akbar , Belete, Habte , Bennett, Derrick , Berhe, Kidanemaryam , Bhagavathula, Akshaya Srikanth , Bhardwaj, Pankaj , Bhat, Anusha Ganapati , Bhattacharyya, Krittika , Bhutta, Zulfiqar A , Bibi, Sadia , Bijani, Ali , Borschmann, Rohan , Borzì, Antonio Maria , Braithwaite, Dejana , Брико, Н. И. , Brugha, Traolach , Budhathoki, Shyam Sundar , Car, Josip , Cárdenas, Rosario , Carvalho, Félix , Castaldelli-Maia, João Maurício , Castañeda-Orjuela, Carlos A , Castelpietra, Giulio , Catalá-López, Ferrán , Cerin, Ester , Chandan, Joht Singh , Chapman, Jens R. , Chattu, Vijay Kumar , Chattu, Soosanna Kumary , Chaudhary, Neha , Cho, Daniel , Choi, Jee-Young J, Chowdhury, Mohiuddin Ahsanul Kabir , Christopher, Devasahayam Jesudas , Chu, Dinh‐Toi , Costa, Vera Marisa , Dávila-Cervantes, Claudio Alberto , Leo, Diego De, Demoz, Gebre Teklemariam , Demsie, Desalegn Getnet , Deribe, Kebede , Desai, Rupak , Nasab, Mostafa Dianati, Silva, Diana Dias da , Forooshani, Zahra Sadat Dibaji, Doyle, Kerrie , Driscoll, Tim , Dubljanin, Eleonora , Adema, Bereket Duko , Eagan, Arielle Wilder , Elemineh, Demelash Abewa , El‐Khatib, Ziad , Ellingsen, Christian Lycke , Eyawo, Oghenowede , Faris, Pawan , Faro, André , Farzadfar, Farshad , Fereshtehnejad, Seyed-Mohammad , Fernandes, Eduarda , Ferrara, Pietro , Fischer, Florian , Foláyan, Morẹ́nikẹ́ Oluwátóyìn , Fomenkov, Artem Alekseevich , Francis, Joel M , Fukumoto, Takeshi , Geberemariyam, Biniyam Sahiledengle, Gebremariam, Hadush, Gebremedhin, Ketema Bizuwork , Gebremeskel, Leake , Gebremeskel, Gebreamlak Gebremedhn , Gebremichael, Berhe , Geta, Birhanu, Ghafourifard, Mansour , Ghamari, Farhad , Gheshlagh, Reza Ghanei , Gholamian, Asadollah , Gilani, Syed Amir , Gill, Tiffany K, Goulart, Alessandra C. , Grada, Ayman , Guo, Yuming , Haagsma, Juanita A. , Hall, Brian J. , Hamadeh, Randah R , Hassan, Shoaib, Hassen, Hamid Yimam , Havmoeller, Rasmus, Heydarpour, Fatemeh , Hı́jar, Martha , Ho, Hung Chak , Hoang, Chi Linh , Hole, Michael K., Hossain, Naznin , Hosseinzadeh, Mehdi , Hostiuc, Sorin , Ibitoye, Segun Emmanuel , Inbaraj, Leeberk Raja , Irvani, Seyed Sina Naghibi , Islam, M. Mofizul , Islam, Sheikh Mohammed Shariful , Ivers, Rebecca , Jahani, Mohammad Ali, Jakovljević, Mihajlo , Jayaraman, Sudha , Jha, Ravi Prakash , John-Akinola, Yetunde O. , Joseph, Nitin , Joukar, Farahnaz, Jürisson, Mikk , Kahsay, Amaha , Kalankesh, Leila R , Kalhor, Rohollah , Kamil, Teshome Abegaz, Kapoor, Neeti , Karami, Manoochehr , Kasaeian, Amir , Kassaye, Hagazi Gebremedhin, Kavetskyy, Taras , Kayode, Gbenga A , Keiyoro, Peter Njenga, Kelbore, Abraham Getachew , Khader, Yousef , Khafaie, Morteza Abdullatif , Khalid, Nauman , Khalil, Ibrahim A, Khalilov, Rovshan , Khan, Maseer , Khan, Ejaz Ahmad , Khan, Junaid , Khanna, Tripti, Khundkar, Roba , Kiirithio, Daniel N, Kim, Yun Jin , Kısa, Sezer , Kısa, Adnan , Komaki, Hamidreza , Kondlahalli, Shivakumar K M, Koolivand, Ali , Korshunov, Vladimir Andreevich , Kraemer, Moritz U. G. , Krishan, Kewal , Defo, Barthélémy Kuate , Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, Manasi , Kumar, Vivek , Kumar, Narinder , Kumaresh, Girikumar, Lami, Faris , Lasrado, Savita , Leasher, Janet L , Li, Shanshan , Liu, Xuefeng , Lyons, Ronan A , Machado, Daiane Borges , Madadin, Mohammed , Razek, Muhammed Magdy Abd El, Mahotra, Narayan Bahadur , Majdán, Marek , Majeed, Azeem , Maled, Venkatesh , Manafi, Navid , Manafi, Amir , Manda, Ana-Laura, Mansour-Ghanaei, Fariborz, Mason‐Jones, Amanda J. , Masoumi, Seyedeh Zahra , Massenburg, Benjamin B. , Maulik, Pallab K , Mehndiratta, Man Mohan, Melketsedik, Zeleke Aschalew , Memiah, Peter , Mendoza, Walter, Menezes, Ritesh G. , Mengesha, Melkamu Merid , Meretoja, Tuomo J , Meretoja, Atte , Merie, Hayimro Edemealem , Miazgowski, Bartosz , Miazgowski, Tomasz , Miller, Ted R. , Mini, GK , Мirrakhimov, Erkin М , Mithra, Prasanna , Moghadaszadeh, Masoud, Mohammad, Yousef , Mohammadian-Hafshejani, Abdollah , Mohammed, Shafiu , Mohammed, Jemal , Bandpei, Mohammad Ali Mohseni, Molokhia, Mariam , Monasta, Lorenzo , Moodley, Yoshan , Moradi, Masoud , Moradi, Ghobad , Morawska, Lídia , Velásquez, Ilais Moreno , Mossie, Tilahun Belete , Musa, Kamarul Imran , Mustafa, Ghulam , Naderi, Mehdi , Nagarajan, Ahamarshan Jayaraman , Naik, Gurudatta , Naimzada, Mukhammad David , Nangia, Vinay, Nascimento, Bruno Ramos , Naserbakht, Morteza , Ndwandwe, Duduzile , Negoi, Ionuţ , Ngunjiri, Josephine W, Nguyen, Cuong Tat , Nguyen, Diep Ngoc , Nikbakhsh, Rajan , Ningrum, Dina Nur Anggraini , Nnaji, Chukwudi A , Ofori‐Asenso, Richard , Ogbo, Felix Akpojene , Oghenetega, Onome Bright , Olagunju, Andrew T , Olagunju, Tinuke O , Bali, Ahmed Omar , Onwujekwe, Obinna , Orpana, Heather , Otstavnov, Nikita , Otstavnov, Stanislav S , Mahesh, P A , Padubidri, Jagadish Rao , Pakhalé, Smita , Pakshir, Keyvan , Panda‐Jonas, Songhomitra, Park, Eun‐Kee , Patel, Sangram Kishor , Pathak, Ashish , Pati, Sanghamitra , Paulos, Kebreab , Pepito, Veincent Christian Filipino , Полибин, Р. В. , Polinder, Suzanne, Pourmalek, Farshad , Pourshams, Akram , Poustchi, Hossein, Prakash, Swayam , Pribadi, Dimas Ria Angga , Puri, Parul , Syed, Zahiruddin Quazi, Rabiee, Navid , Radfar, Amir , Rafay, Anwar, Rafiee, Ata , Rafiei, Alireza , Rahim, Fakher , Rahman, Muhammad Aziz , Rajabpour-Sanati, Ali, Rajati, Fatemeh , Rakovac, Ivo , Rao, Sowmya J, Rashedi, Vahid , Rawal, Lal , Rawassizadeh, Reza , Renjith, Vishnu , Resnikoff, Serge , Rezapour, Aziz, Rickard, Jennifer , Saddik, Basema , Safdarian, Mahdi , Sajadi, S. Mohammad , Salamati, Payman, Salem, Marwa Rashad , Salem, Hosni , Salz, Inbal, Samy, Abdallah M , Sanabria, Juan , Sànchez-Riera, Lídia , Sarveazad, Arash , Sathian, Brijesh , Sawhney, Monika, Schwebel, David C. , Seedat, Soraya , Senthilkumaran, Subramanian , Seyedmousavi, Seyedmojtaba , Sha, Feng , Shaahmadi, Faramarz , Shaikh, Masood Ali , Shams-Beyranvand, Mehran , Shigematsu, Mika, Shin, Jae Il , Shiri, Rahman , Sigfúsdóttir, Inga Dóra, Singh, Pankaj Kumar , Sinha, Dhirendra Narain , Soriano, Joan B. , Soyiri, Ireneous N , Sufiyan, Mu’awiyyah Babale , Sykes, Bryan L. , Tabarés‐Seisdedos, Rafael , Tabb, Karen M. , Wogayehu, Biruk , Tefera, Yibekal Manaye , Tekulu, Gebretsadkan Hintsa , Kassie, Ayenew , Титова, М. В. , Tlaye, Kenean Getaneh , Tohidinik, Hamid Reza , Topór-Mądry, Roman , Tripathy, Jaya Prasad , Tsai, Alexander C. , Tsatsakis, Aristidis , Car, Lorainne Tudor , Ullah, Irfan , Ullah, Saif , Upadhyay, Era , Valdéz, Pascual , Violante, Francesco Saverio , Waheed, Yasir , Wang, Yuan‐Pang , Wiangkham, Taweewat , Wolde, Haileab Fekadu , Woldeyes, Dawit Habte , Wu, Ai-Min, Wyper, Grant M. A. , Yadav, Rajaram , Yadollahpour, Ali , Yano, Yuichiro , Yaya, Sanni , Yazdi‐Feyzabadi, Vahid , Ye, Pengpeng , Yisma, Engida , Yoon, Seok‐Jun , Youm, Yoosik , Younis, Mustafa Z , Yousefi, Zabihollah , Yu, Yong , Moghadam, Telma Zahirian , Zaman, Sojib Bin , Zarei, Fatemeh , Zhang, Zhi-Jiang, Zhang, Yunquan , Zodpey, Sanjay , Dandona, Rakhi , Dharmaratne, Samath Dhamminda , Hay, Simon I , Mokdad, Ali H. , Reiner, Robert C. , Vos, Theo , Topór‐Mądry, Roman , Feyissa, Garumma Tolu , Haghparast‐Bidgoli, Hassan , Kumar, G Anil , Zahiruddin, Quazi Syed , Dianatinasab, Mostafa , Sanati, Ali Rajabpour , Baig, Atif Amin , Kumar, Vivek , Castaldelli-Maia, João M , Farzadfar, Farshad , Shin, Jae I L , Islam, Sheikh Mohammed Shariful , Rahman, Muhammad Aziz , Bhagavathula, Akshaya Srikanth , Belete, T , Liu, Zichen , Roberts, Nicholas L S , Henry, Nathaniel J , Abdollahpour, Ibrahim , Adsuar, José Carmelo , Ahmed, Muktar Beshir , Ahmed, Rushdiá , Alghnam, Suliman Abdullah , Ali, Saqib , Alinia, Cyrus , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Antonio, Carl Abelardo T. , Arab-Zozani, Morteza , Asaad, Malke , Balachandran, Arun , Banach, Maciej , Bayati, Mohsen , Bazargan‐Hejazi, Shahrzad , Bedi, Neeraj , Behzadifar, Masoud , Benseñor, Isabela M. , Boloor, Archith , Borges, Guilherme , Boufous, Soufiane , Chatziralli, Irini , Cicuttini, Flavia , Coelho, João M, Dahlawi, Saad M A , Daryani, Ahmad , Demeke, Feleke Mekonnen , Forooshani, Zahra Sadat Dibaji, Do, Hoa , Duko, Bereket , El-Jaafary, Shaimaa I , Zaki, Maysaa El Sayed , Eskandarieh, Sharareh , Foroutan, Masoud , Franklin, Richard C. , Gebremariam, Hadush, Gedefaw, Getnet , Bante, Agegnehu , Gill, Tiffany K. , Goudarzian, Amir Hossein , Grivna, Michal , Guimarães, Rafael Alves , Gupta, Gaurav Kumar , Hamidi, Samer , Handiso, Demelash Woldeyohannes , Haro, Josep María , Hasanzadeh, Amir , Hassanipour, Soheil , Hassankhani, Hadi , Hendrie, Delia V. , Holla, Ramesh , Hu, Guoqing , Ilesanmi, Olayinka Stephen , Jalilian, Farzad , Jayatilleke, Achala Upendra , Jonas, Jost B , Jones, Kelly , Jozwiak, Jacek Jerzy , Jungari, Suresh Banayya , Kabir, Ali , Kanchan, Tanuj , Khalil, Ibrahim A, Khazaei, Salman , Khazaie, Habibolah , Kim, Young‐Eun , Kim, Daniel , Shivakumar, KM , Koyanagi, Ai , Kumar, Nithin , Lansingh, Van Charles , Latifi, Arman , Lauriola, Paolo , Vecchia, Carlo La , Lee, Shaun Wen Huey , Lopez, Alan D , Lotufo, Paulo A. , Malta, Déborah Carvalho , Manjunatha, Narayana , Mansour‐Ghanaei, Fariborz , Mansournia, Mohammad Alì , Maravilla, Joemer Calderon , Aschalew, Zeleke , Meštrović, Tomislav , Mirică, Andreea , Mirzaei-Alavijeh, Mehdi, Moazen, Babak , Mohamadi, Efat , Darwesh, Aso Mohammad , Mohammadpourhodki, Reza , Mohebi, Farnam , Moradi‐Lakeh, Maziar , Moradzadeh, Rahmatollah , Morrison, Shane D. , Muluneh, Atalay Goshu , Najafi, Farid , Nayak, Vinod C , Nazari, Javad , Nguyen, Trang Huyen , Nguyen, Huong Lan Thi , Oh, In‐Hwan , Ota, Erika , Peden, Amy E. , Pereira, Jeevan , Phillips, Michael , Rabiee, Mohammad , Rahimi, Siavash , Rastogi, Prateek , Rathi, Priya , Rawaf, Salman , Ribeiro, Ana Isabel , Ríos-González, Carlos Miguel , Roever, Leonardo , Ronfani, Luca , Roshandel, Gholamreza , Safarpour, Hamid , Salamati, Payman, Santric-Milicevic, Milena M , Sarker, Abdur Razzaque , Sayyah, Mehdi , Shahabi, Saeed , Sheikh, Aziz , Siabani, Soraya , Singh, Ambrish , Soheili, Amin , Sorrie, Muluken Bekele , Stokes, Mark Andrew , Tehrani‐Banihashemi, Arash , Tesfay, Berhe Etsay , Thapar, Rekha , Tran, Khanh Bao , Tran, Bach Xuan , Unnikrishnan, Bhaskaran , Uthman, Olalekan Abdulrahman , Vasankari, Tommi Juhani , Veisani, Yousef , Venketasubramanian, Narayanaswamy , Vlassov, Vasily , Wondmeneh, Temesgen Gebeyehu , Wondmieneh, Adam Belay , YIP, PAUL S. F. , Yonemoto, Naohiro , Yu, Chuanhua , Zaidi, Zoubida , Zamani, Mohammad , Zandian, Hamed , Zhang, Zhi‐Jiang , Ziapour, Arash , Pigott, David M. , Olagunju, Andrew T , Baig, Atif Amin , Desai, Rupak , Alahdab, Fares , Rahim, Fakher

Mayo Clinic

Injury Prevention | August 24, 2020 | Volume: 26 | Issue: Suppl 2 | Pages: i125-i153

10.1136/injuryprev-2019-043531 | PMID 32839249 Get It

Background While there is a long history of measuring death and disability from injuries, modern research methods must account for the wide spectrum of disability that can occur in an injury, and must provide estimates with sufficient demographic, geographical and temporal detail to be useful for policy makers. The Global Burden of Disease (GBD) 2017 study used methods to provide highly detailed estimates of global injury burden that meet these criteria. Methods In this study, we report and discuss the methods used in GBD 2017 for injury morbidity and mortality burden estimation. In summary, these methods included estimating cause-specific mortality for every cause of injury, and then estimating incidence for every cause of injury. Non-fatal disability for each cause is then calculated based on the probabilities of suffering from different types of bodily injury experienced. Results GBD 2017 produced morbidity and mortality estimates for 38 causes of injury. Estimates were produced in terms of incidence, prevalence, years lived with disability, cause-specific mortality, years of life lost and disability-adjusted life-years for a 28-year period for 22 age groups, 195 countries and both sexes. Conclusions GBD 2017 demonstrated a complex and sophisticated series of analytical steps using the largest known database of morbidity and mortality data on injuries. GBD 2017 results should be used to help inform injury prevention policy making and resource allocation. We also identify important avenues for improving injury burden estimation in the future.